Kiparski A v, Frei D, Fierz W, Frei G, Uhlschmid G, Largiader F, Binswanger U
Nephrologische Station, Universitätsspital Zürich.
Klin Wochenschr. 1990 Apr 17;68(8):408-14. doi: 10.1007/BF01648582.
The lymphocyte subsets in the peripheral blood were examined 3 times a week in 17 patients receiving a cadaveric renal allograft using 2-color flow cytometry and several combinations of monoclonal antibodies. Patients who experienced a rejection crisis (n = 12) had a significantly higher CD4/CD8-ratio (2.72 +/- 1.26 mean +/- SD) than patients with stable graft function (1.76 +/- 1.33, p less than 0.05). 9/12 patients showed 0-3 days prior to the rejection episode an increase of the CD4/CD8- ratio (greater than or equal to 0.5) and/or a high ratio (greater than or equal to 2.5) with a decrease following antirejection therapy. The activation markers HLA-DR and IL-2 receptor on T cells were increased only during 3/12 rejection episodes. Patients with rejections resistant to prednisone pulse therapy (n = 6) had significantly more lymphocytes/mm3 in the peripheral blood (1111.7 +/- 597.5) than successfully treated patients (n = 6, 336.7 +/- 196.0, p less than 0.02). Antirejection therapy with prednisone pulses and/or antithymocyte globuline resulted in a significant decrease of T lymphocytes (CD3+) with a selective reduction of T helper/inducer cells (CD4+). 6 months after renal transplantation the patients had a higher percentage of suppressor/cytotoxic cells (CD8+) compared to the pretransplant values (26.3 +/- 10.9% vs 17.7 +/- 6.2%, p less than 0.02) and blood donors (16.3 +/- 6.2%, p less than 0.01). Furthermore the percentage of T helper cells (CD4+/CD28-) was significantly higher and the T suppressor-inducer cells (CD4+/CD28+) were significantly lower compared to the controls. Serial flow cytometric determinations of lymphocyte subsets in renal allograft recipients may be helpful in some cases although rejection episodes could not be predicted in the individual patient.
采用双色流式细胞术及几种单克隆抗体组合,每周3次检测17例接受尸体肾移植患者外周血中的淋巴细胞亚群。经历排斥危机的患者(n = 12)的CD4/CD8比值(平均±标准差为2.72±1.26)显著高于移植肾功能稳定的患者(1.76±1.33,p<0.05)。12例患者中有9例在排斥发作前0 - 3天CD4/CD8比值升高(≥0.5)和/或比值较高(≥2.5),抗排斥治疗后下降。T细胞上的活化标志物HLA - DR和IL - 2受体仅在12次排斥发作中的3次期间升高。对泼尼松脉冲治疗耐药的排斥患者(n = 6)外周血中的淋巴细胞/mm3显著多于成功治疗的患者(n = 6,336.7±196.0,p<0.02)。泼尼松脉冲和/或抗胸腺细胞球蛋白的抗排斥治疗导致T淋巴细胞(CD3 +)显著减少,T辅助/诱导细胞(CD4 +)选择性减少。肾移植6个月后,患者的抑制/细胞毒性细胞(CD8 +)百分比高于移植前值(26.3±10.9%对17.7±6.2%,p<0.02)和献血者(16.3±6.2%,p<0.01)。此外,与对照组相比,T辅助细胞(CD4 + /CD28 -)百分比显著更高,T抑制诱导细胞(CD4 + /CD28 +)显著更低。尽管无法在个体患者中预测排斥发作,但对肾移植受者进行淋巴细胞亚群的系列流式细胞术测定在某些情况下可能会有所帮助。